VitaSpring Biomedical Co. Ltd.
VSBC · OTC
10/31/2022 | 7/31/2022 | 4/30/2022 | 1/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $3 |
| % Growth | – | -100% | -57.3% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $2 |
| Gross Profit | -$0 | -$0 | $1 | $1 |
| % Margin | – | – | 38.1% | 41.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | $1 |
| % Margin | – | – | 23% | 34.1% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | $1 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | $1 |
| % Margin | – | – | 18.6% | 27% |
| EPS | -0.001 | -0.001 | 0.001 | 0.005 |
| % Growth | 0% | -153.8% | -71.7% | – |
| EPS Diluted | -0.001 | -0.001 | 0.001 | 0.005 |
| Weighted Avg Shares Out | 207 | 207 | 207 | 207 |
| Weighted Avg Shares Out Dil | 207 | 207 | 207 | 207 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | $1 |
| % Margin | – | – | 23.3% | 34.2% |